We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Interferon-Lambda Prevents West Nile Virus from Crossing the Blood-brain Barrier

By LabMedica International staff writers
Posted on 24 May 2015
Print article
Image: Mosquitoes are known to infect people and animals with West Nile virus. Studying West Nile virus infection in mice, researchers have shown that the antiviral compound interferon-lambda tightens the blood-brain barrier, making it harder for the virus to invade the brain (Photo courtesy of the CDC – [US] Centers for Disease Control and Prevention).
Image: Mosquitoes are known to infect people and animals with West Nile virus. Studying West Nile virus infection in mice, researchers have shown that the antiviral compound interferon-lambda tightens the blood-brain barrier, making it harder for the virus to invade the brain (Photo courtesy of the CDC – [US] Centers for Disease Control and Prevention).
The cytokine interferon-lambda prevents West Nile virus from infecting brain cells by reducing transport of large molecules across the blood-brain barrier.

Although interferon-lambda [also known as type III interferon or interleukin-28 (IL-28)/IL-29] was known to restrict infection by several viruses, its inhibitory mechanism had not been determined. To explain the protective effect of interferon-lambda, investigators at the Washington University School of Medicine (St. Louis, USA) worked with cultures of mouse keratinocytes and dendritic cells and with a line of mice that had been genetically engineered to lack the gene for the interferon-lambda receptor (IFNLR1).

Experiments with cell cultures failed to show a direct antiviral effect of added interferon-lambda, even though expression of interferon-stimulated genes was induced.

In animal studies, normal mice and mice lacking the IFNLR1 gene were treated with interferon-lambda at the same time they were infected with the West Nile virus. The mice received additional interferon-lambda treatments two and four days following infection.

Results published in the April 22, 2015, online edition of the journal Science Translational Medicine revealed that there were no differences in West Nile virus burden between normal and mutant mice in the draining lymph nodes, spleen, or blood. On the other hand, there was increased West Nile virus infection in the brain and spinal cord of the mutant mice, but this was not associated with a direct antiviral effect in mouse neurons. Ultimately it was seen that while typically less than 20% of normal, untreated mice survived such a high dose of the virus, survival rates rose to more than 40% of the mice treated with interferon-lambda.

Additional experiments revealed that treatment of mice with pegylated interferon-lambda resulted in decreased blood-brain barrier permeability, reduced West Nile virus infection in the brain without affecting the number of virus particles in the blood, and improved survival against lethal virus challenge. An in vitro model of the blood-brain barrier showed that interferon-lambda signaling in mouse brain microvascular endothelial cells increased electrical resistance, decreased virus movement across the barrier, and modulated tight junction protein localization in protein synthesis.

"Viruses are most dangerous when they enter the brain," said senior author Dr. Michael Diamond, professor of medicine at the Washington University School of Medicine. "Compared with untreated mice, we found significantly lower concentrations of the virus in the brain among mice treated with interferon-lambda. Interferon-lambda has significantly fewer receptors in the body, which may mean using it as a treatment is likely to have fewer side effects. It is also possible that interferon-lambda may influence other protective barriers in the body, such as those in the skin and the gut, an area of research my laboratory is investigating."

Related Links:

Washington University School of Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.